Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
Ye Won ChungSeongmin KimJin Hwa HongJae Kwan LeeNak Woo LeeYoung Seok LeeJae Yun SongPublished in: Journal of gynecologic oncology (2020)
HER3 is possibly an independent marker for poor prognosis in individuals with ovarian cancer, as the HER3 signalling pathway is distinct from that of HER2. The possibility of targeted therapy for patients with HER3 alteration in ovarian cancer should be evaluated.